Apimeds Pharmaceuticals Inc. Insider Trading
APUS
No open-market buying or selling by insiders.
The last open-market buy by an executive or director was in May 2025.
Get an email when APUS's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| May 13, 2025 – May 14, 2025 | Christopher Kim Chairman and CMO | Bought 2 parts | 27,500 | $1.83 average | 50K | New | Form 4 |
| May 12, 2025 | Jakap Koo Director | Bought | 28,500 | $1.99 | 57K | 4.6% | Form 4 |
- May 13, 2025 – May 14, 2025Christopher KimChairman and CMO · bought 27,500 at avg $1.8350KNew position
- May 12, 2025Jakap KooDirector · bought 28,500 at $1.9957K4.6% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with APUS
Spot a number that looks wrong? Check it in APUS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing APUS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.